The direction of therapy is chosen based on tumor morphology, its grade and size, the presence of metastases to the lymph nodes, as well as gene expression of BC critical markers: ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [5]. This evidence concerns the gene PGR and breast cancer.